Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | DPP4 | P27487 | 7/20 | 0.36 |
| ▸ | USP2 | O75604 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | FAP | Q12884 | 3/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | MRE11 | P49959 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2962138 | 0.93 | DPP4 (0.37) | HTR2CDPP4FAPDPP9 | |
| SCHEMBL2968285 | 0.89 | MAOB (0.34) | DPP4FAP | |
| SCHEMBL2952804 | 0.89 | DPP4 (0.35) | DPP4USP2ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL2962543 | 0.88 | DPP4 (0.31) | DPP4 | |
| SCHEMBL2964934 | 0.88 | DPP4 (0.35) | DPP4FAPDPP9 | |
| SCHEMBL2961124 | 0.87 | DPP4 (0.36) | DPP4ALDH1A1HIF1AFAP | |
| SCHEMBL2963923 | 0.86 | DPP4 (0.31) | DPP4 | |
| SCHEMBL2965131 | 0.86 | DPP4 (0.34) | DPP4FAPDPP9 | |
| SCHEMBL2966874 | 0.85 | DPP4 (0.33) | DPP4FAPDPP9 | |
| SCHEMBL2958725 | 0.85 | DPP4 (0.33) | DPP4FAPDPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20060100199-A1 | Novel condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060063787-A1 | Condensed imidazole derivatives | EISAI CO., LTD. (JP) | 2006-03-23 | — | — | US | disclosed |
| EP-1514552-A1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | Eisai Co., Ltd. (JP) | 2005-03-16 | — | — | EP | disclosed |
| US-20040116328-A1 | Condensed imidazole derivatives | EISAI CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100199-A1 | Novel condensed imidazole derivatives | H1-2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-4 | HTR2C 805/4885DPP4 4422/4885USP2 1695/4885 |
| US-20060063787-A1 | Condensed imidazole derivatives | DPP4, HDAC1, DPP7 | HTR2C 1288/4885DPP4 1/4885USP2 2053/4885 |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | DPP4, HDAC1, DPP7 | HTR2C 1288/4885DPP4 1/4885USP2 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.